CompletedNCT00246272

Rapid-dissolving risperidone tablets after switching from regular tablets

About this title

Medication studyAges 18+Schizophrenia

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Study clarity

Study start dateOctober 2004

Recruitment status: Completed
Enrollment listed in the registry: 82
Sponsor: Janssen-Ortho Inc., Canada
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Not clearly listed
Age range: Over 18 Years
Official registry ID: NCT00246272
Official title: Show the full official title
An Open-label Study Evaluating the Maintenance of Clinical Effect in Adults With Schizophrenia Switched From RISPERDAL® Tablets (Risperidone) to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone

Completed

Locations not listed

FAQ

Who is behind this study?

The study sponsor is Janssen-Ortho Inc., Canada.

Did this study involve medication?

Yes. The study involved medication, including risperidone.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.